The anti-vascular endothelial
growth factor drugs ranibizumab and aflibercept, used to treat vision loss from diabetic macular edema (DME), and approximately 20 to 30 times more expensive than bevacizumab, are not cost - effective for treatment of DME compared to bevacizumab unless their prices
decrease substantially, according to a study published online by JAMA Ophthalmology.
But in his book, Dr. Lomborg cites figures from the United States Census Bureau, the International Monetary Fund, the World Bank and the European Environment Agency to show that the rate of world population
growth has actually been dropping sharply since 1964; the level of international debt
decreased slightly from 1984 to 1999; the price of oil, adjusted for inflation, is half what it was in the early 1980's; and the sulfur emissions that generate acid rain (which has turned out to do little if any damage to forests, though some to lakes) have been cut
substantially since 1984.